Spirax Group beats profit forecasts, shares jump

Spirax Group reported adjusted operating profit of £339.9m for 2025, beating analyst estimates of £332m, with revenue £1,702.9m and organic revenue growth of 5%. Adjusted operating margin improved 30bps to 20.0% (organic), adjusted cash conversion rose to 89% and leverage fell to 1.5x; a restructuring generated £40m of annualized savings (half realised in 2025). Steam Thermal Solutions and other divisions delivered mixed but positive organic growth (1–11% across divisions), the board proposed a final dividend of 121.1p (total 170.0p, +3% YoY) and the company expects mid-single-digit organic sales growth and further margin progress for 2026.

Analysis

Spirax’s playbook — harvesting restructuring savings to front-load go-to-market and digital investments — is a quality uplift rather than a one-off margin pop. If those investments convert at scale, I expect operating leverage to compound: a plausible 150–300bp improvement in structural margins over 12–24 months would re-rate the stock versus bulk industrial peers because it shifts revenue mix into higher-velocity, higher-margin niches.

Second-order winners include specialist OEM suppliers and control/software vendors serving biopharma and semiconductor process lines; increased sales coverage and digital connectivity tends to pull more long-tail aftermarket spend into branded service contracts, squeezing smaller aftermarket competitors. Conversely, broad-based steam/commodity equipment vendors face margin pressure as Spirax moves up the value chain and wins OEM/service share in targeted verticals.

Key near-term risks are cyclical: a semiconductor or biopharma capex pause would show up quickly in order intake and could reverse margin momentum within 2–6 quarters. Execution risk on the remaining restructuring savings and on cross-selling new digital offerings is material — failure to convert will compress the implied multiple and could knock 10–20% off consensus 12-month price expectations.

Monitor three catalysts: order intake trends (next 1–3 quarters) to validate demand shift, additional cost-realization milestones (6–12 months) to de-risk margin targets, and any bolt-on M&A or buyback activity that would signal management confidence. The stock is a medium-term asymmetric opportunity if you buy on weakness and protect downside while waiting for structural margin conversion.

Key Decisions for Investors

• Long SPX.L (Spirax Group) — 12 month horizon. Size 3–5% NAV on entry; trim into strength. Target 20–30% upside if margin conversion runs to plan; stop -12% on failure to show sequential order intake improvement over two quarters.
• Pair trade: Long SPX.L / Short IMI.L (notional neutral) — 12–18 month horizon. Play structural mix shift and aftermarket capture while hedging macro cyclicality; expect spread to widen (alpha target 8–12%). Close if spread compresses >5% or if both companies report synchronous order weakness.
• Options hedge: Buy 9–12 month puts on SPX.L sized to cap downside to -12% while holding the equity core. Fund with selling covered calls 6–9 months out if you want to reduce carry; R/R asymmetric (limited downside, full upside to call strike).
• Event trade: Add or scale into SPX.L on any >5% post-earnings dip that is not accompanied by a miss in order intake or guidance withdrawal — these dips historically offer better downside protection given recurring aftermarket revenue.